Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Rare Disease
Sort By
Newest First
1 / 1
1 / 1
Clinical Trials
Passion and Understanding Essential for Rare Disease Clinical Trials
Juliet Moritz
Ergomed
PAO-10-24-CL-03
Oct 29, 2024
Clinical Trials
Optimizing Oncology and Rare Disease Clinical Trials by Focusing on Science and Aligning with both Patients and Investigators
Dave Selkirk
Ergomed
PAO-06-24-CL-09
May 30, 2024
Rare Diseases
Staying Agile to Bring Therapies to Patients with Rare Diseases
Sheila Frame
Amryt Pharma
PAO-06-022-CL-08
Jun 21, 2022
Rare Disease Clinical Trials
Rare Disease Patients Benefit from Clinical Trial Flexibility
Tim Rich; Meredith McCumbee; Francis Jones, Ph.D.
PPD, part of Thermo Fisher Scientific
PAO-02-022-CL-03
Mar 12, 2022
Rare Diseases
Leveraging AI and RNA to Fight Rare Diseases
Envisagenics
PAO-02-22-R250-17
Feb 24, 2022
Gene Therapy
Beyond 2020: Looking into the Crystal Ball for Gene Therapy
Ratish Krishnan
MilliporeSigma
PAO-01-21-CL-03
Feb 01, 2021
Endocrine Diseases
Developing Transformative Treatments for Rare Endocrine Diseases
Abraham N. Ceesay
Tiburio Therapeutics
PAP-Q2-20-CL-023
Jul 01, 2020
Drug Approval
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
Pfizer
PR-M05-19-NI-036
May 13, 2019
Clinical Trial Logistics
Facilitating Complex Clinical Trials For Rare Diseases
Ariette van Strien
Marken
PAP-Q1-2019-CL-003
Mar 12, 2019
Cell and Gene Therapy
REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
REGENXBIO
PR-M11-18-NI-028
Nov 08, 2018
Drug Development
Patients with Rare Leukemia Disease Will Have New Treatment Option
Nigel Walker
Nice Insight
PAO-M09-18-NI-016
Sep 21, 2018
Business
Expansion Therapeutics Raises $55.3 Million in Series A Financing to Advance Portfolio of Novel RNA Targeted Small Molecule Medicines to Treat Rare Diseases
Expansion Therapeutics, Inc.
PR-M01-18-NI-009
Jan 03, 2018